SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Granules India receives EIR from USFDA for Jeedimetla facility

31 May 2016 Evaluate

Granules India has received the Establishment Inspection Report (EIR) from the USFDA for the inspection conducted at its Jeedimetla facility in December 2015.

The USFDA has acknowledged receipt of its responses sent on January 7 and March 28, 2016 on the observations issued by it for the Jeedimetla facility. The USFDA closed the matter and issued EIR for the Jeedimetla facility situated in the state of Telangana.

Granules India produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) for quality conscious customers in the regulated and semi-regulated markets.


Granules India Share Price

654.40 3.60 (0.55%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×